Immune Reconstitution in MS:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Evolving Therapeutic Landscape in MS

Barts-MS T2T-NEDA Algorithm

Defining IRT and Maintenance Therapy

Maintenance Therapies vs IRTs

Maintenance Therapies vs IRTs: Attributes

Treatment Burden of DMTs in MS

DMT Adherence in MS

Monitoring Burden With DMTs in MS

Daclizumab

Immunosuppression

Continuous vs Short-Term Immunosuppression

Immunosuppression Risks Over Time

Fingolimod

Natalizumab

Alemtuzumab

Alemtuzumab Risks Identified in Clinical Trials

Cladribine

De-Risking Immunosuppression

Maintenance Therapies vs IRTs: Vaccines and Pregnancy

Case Study 1

Vaccinations

Pregnancy

Pregnancy (cont)

Pregnancy (cont)

Defining an MS Cure?

10-Year Durable Efficacy of Alemtuzumab CAMMS223

CIS Conversion to MS With Cladribine

Case Study 2

NEDA Rates in Phase 3 Trials

Flipping the Pyramid in MS

A New Classification of DMTs for RMS

Personalizing Therapy

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)